Shattuck Labs Announces Pricing of Upsized Initial Public Offering

Shattuck Labs, Inc. (Shattuck), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of cancer and autoimmune disease, today announced the pricing of its upsized initial public offering of 11,882,352 shares of common stock at a public offering price of $17.00 per share.